InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Engages JBN Partners LLC, Completes Target-Based Model for AI-Driven Drug Discovery Program
January 10, 2022

InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Engages JBN Partners LLC, Completes Target-Based Model for AI-Driven Drug Discovery Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, has announced its engagement of JBN Partners LLC to increase public awareness of and interest in the company, its management and its products. Under the collaboration, JBN will coordinate certain investor relations and corporate financial public relations with members of the investment community, the financial media and the general public. The services agreement with JBN has a term of six months with a total payment value of $150,000.

In addition, the company today announced that it has completed a target-based model of the classic psychedelic serotonin receptor “5-HT 2A” for use in its AI-driven drug discovery program. According to the update, the model will allow Mydecine to expeditiously screen billions of structures to determine which novel compounds are most likely to increase binding affinity, enabling the company to continue creating improved second- and third-generation psychedelic molecules for medical use. “AI gives us an incredibly robust tool for screening potential novel psychedelic compounds,” said Mydecine’s Chief Science Officer Rob Roscow. “This screening gives us increased confidence in investing in the later stages of our drug development and enables rapid development in our pipeline.”

To view the full press releases, visit https://ibn.fm/XnzIQ and https://ibn.fm/BRGKf

About Mydecine Innovations Group

Mydecine is a biotechnology and digital technology company developing innovative first-and-second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure. Mydecine was founded in 2020 on the guiding principle that there is a significant unmet need and lack of Innovations in the mental health and treatment environments. The company is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. Mydecine’s business model combines clinical trials and data outcome, technology, scientific and regulatory expertise, focusing on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way mental health disorders are treated. The company’s vision is to bridge the current gap between what the cognitive healthcare system currently provides with the needs of the patients. Mydecine is headquartered in Denver, Colorado, USA, with international offices in Leiden, Netherlands. For more information about the company, please visit www.Mydecine.com.

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).